3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other solid neoplasm
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Prostatic Neoplasms
5
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Sarcoma, Ewing
1
Sarcoma, Clear Cell
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Retinoblastoma
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Hepatoblastoma
1
Cardiovascular Diseases
1
Carcinoma, Renal Cell
1
Interventions
X-Rays
4
Phantoms, Imaging
4
Cyclophosphamide
4
Specimen Handling
3
Melphalan
3
Magnetic Resonance Spectroscopy
3
Granulocyte Colony-Stimulating Factor
3
Busulfan
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
talazoparib
2
selpercatinib
2
palbociclib
2
ivosidenib
2
fludarabine
2
cabozantinib
2
Vemurafenib
2
Topotecan
2
Temozolomide
2
Sirolimus
2
Nuclear Medicine Department, Hospital
2
Nivolumab
2
LY3023414
2
Filgrastim
2
Bone Marrow Transplantation
2
trioctyl phosphine oxide
1
regorafenib
1
racotumomab
1
pembrolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma, Ewing
×
Simvastatin
×
Genitourinary
×
Clear all
NCT02390843
2020-04-03
AflacST1402
Emory University
Phase 1
Completed
13 enrolled